Key facts
- This page summarizes James Hassard's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Jul 2024, 18:04.
James Hassard - 05 Jul 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- CRNX
- Reported as of
- 05 Jul 2024
- Net transaction value
- -$365,250
- SEC form
- 4
- Accepted by SEC
- 09 Jul 2024, 18:04:39 UTC
- Prior SEC filing
- 24 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- Marc Wilson, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
James Hassard filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 09 Jul 2024.
Change
- Previous filing in this sequence was filed on 24 Jun 2024.
- Current net transaction value: -$365,250.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- $295,950
- Shares
- +15,000
- Change %
- +51%
- Price
- $19.73
- Shares after
- 44,259
- Date
- 05 Jul 2024
- Ownership
- Direct
CRNX
transaction
Common Stock
Sale
- Transaction value
- $661,200
- Shares
- -15,000
- Change %
- -34%
- Price
- $44.08
- Shares after
- 29,259
- Date
- 05 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Stock option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,000
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 130,000
- Date
- 05 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $19.73
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.08 per share. The range of sales prices on the transaction date was $43.71 to $44.41 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Footnote F3
The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.